NOVATO, CA, (Monday, June 18, 2012) – Biosearch Technologies, Inc. (Biosearch), a leading supplier of sophisticated oligonucleotide components to the rapidly growing molecular diagnostics industry, today announced that the company has launched catalogued assays for Stellaris™ RNA FISH. These assays fall into three groups – well characterized RNA targets (“foundation genes”) suitable for use as positive controls, oncogenes, and key mRNAs in the hypusine pathway. Scientists can use these products to pursue research using RNA FISH and combine them into multiplexed assays with probes targeting other RNA transcripts or even protein targets. For example, immunofluorescence (IF) techniques may be readily combined with Stellaris RNA FISH.
Biosearch announced on August 5th 2010 that the company had licensed exclusive rights to a fluorescent in situ hybridization (FISH) technology for detection of single molecules of RNA. Biosearch owns the exclusive rights to manufacture, catalogue and sell RNA FISH probes, assays and kits into the Research, Applied Markets and in vitro diagnostics (IVD) fields under the UMDNJ technologies and patent applications, and currently makes these products available as Stellaris RNA FISH probes.
The launch of catalogued Stellaris products will significantly improve ease of use for the Stellaris technology by providing convenient positive controls, and reducing uncertainty associated with designing an untested probe set against a new RNA target. Cancer research may benefit from the assays designed against prevalent oncogenes, and upcoming additions of cancer related RNA targets. The team at Biosearch also plans to provide the same advantages in the future to developmental biology, neuroscience, and other specialties.
This product is sold under license from the University of Medicine and Dentistry of New Jersey and may be used under its patent rights for Research Use Only.
About Biosearch Technologies, Inc.
Biosearch Technologies, Inc. is a privately held, ISO 9001:2008 certified company, located in northern California. Founded in 1993, Biosearch is a leader in the design, development and manufacture of sophisticated oligonucleotide-based tools. Products include fluorophores (CAL Fluor®, Quasar® and Pulsar® dyes) and dark quenchers (Black Hole Quencher® dyes) to be included in custom-synthesized probe formats for real-time, quantitative PCR, Stellaris RNA FISH, and other genomic-based applications.
In addition to basic R&D applications, Biosearch now leverages its demonstrated expertise in fully assembled RUO kits and in the cGMP manufacture of oligonucleotide components for molecular diagnostic assays. Biosearch Technologies is registered with the FDA (registration number 300300905), and licensed by the State of California Department of Public Health (license number 55563) as a medical device manufacturer. As such, its GMP and Commercial Services manufacturing processes conform to all applicable cGMP requirements per 21 CFR Part 820. Biosearch’s markets include pharmaceutical, in vitro diagnostic, biotechnology, ag/bio, environmental and food testing, public health, and biodefense sectors.
For additional information about Biosearch Technologies, Inc., contact email@example.com or visit www.biosearchtech.com.